MsNatasha Stevens

(she/her)

Senior Program Manager - Multiple Sclerosis Research Flagship

Menzies Institute for Medical Research

  • Senior Program Manager - Multiple Sclerosis Research Flagship
    Menzies Institute for Medical Research

RESEARCH SUMMARy

Natasha has directly managed the design, conduct and completion of 12 multicentre, randomised, controlled trials (RCTs) and provided quality assurance and operational oversight for more than 50 RCTs. Her experience focusses on investigator led trials in Australia and the UK, from phase I to phase III, drug, device, advanced therapy, and complex interventional trials, with experience implementing parallel, cross over, cluster randomised, and step wedged designs. This experience extends to various therapeutic areas, including human immunodeficiency virus (HIV), Epstein Barr virus (EBV), cancer (nasopharyngeal carcinoma (NPC) and glioblastoma), respiratory diseases, women’s health, functional bowel disorders and multiple sclerosis (MS). This extensive and varied experience in implementing clinical trials, provides a unique understanding of national and international clinical trial regulations and guidelines, including European Union (EU) and United States (FDA), Australian (TGA), and UK (MHRA) regulatory environments, with practical application of ethics and governance requirements, clinical trial feasibility and protocol implementation, database design, data management, quality control, quality assurance and monitoring to audit standards, along with advanced finance, governance, reporting, and stakeholder management experience, with a particularly keen interest in consumer and community involvement in research, clinical trial methodology, research translation and impact.

 

FUNDED PROJECTS

  • CONSULTANCY/CONTRACT RESEARCH
    PLatform Adaptive Trial for remYelination and neuroProtection in mUltiple Sclerosis (PLATYPUS)
    8 Jul 2026 - 15 Mar 2030
    People funded by this grant:
    • Taylor B,
    • Foong YC,
    • Stevens N,
    • Ng YZJ,
    • Young K
    Project Total: $95,220; A multicentre, interventional, multi-arm, multi-stage trial including randomisation, double blinding, placebo control evaluation of treatments for slowing the progression of disability in participants with Secondary Progressive Multiple Sclerosis (SPMS) and Primary Progressive Multiple Sclerosis (PPMS), together termed Progressive Multiple Sclerosis (PMS). Funded by: Multiple Sclerosis Australia; Griffith University; MSWA; University of Tasmania.
  • GRANT
    Centre of multiple sclerosis research translation
    1 Jul 2024 - 30 Jun 2029
    People funded by this grant:
    • Young K,
    • Taylor B,
    • Reay W,
    • van der Mei I,
    • Zhou Y
    Project Total: $3,000,000; Multiple Sclerosis (MS) is a disease that causes inflammation in the brain. People with MS need treatments that will protect and repair the brain. In our MS Centre, people with MS, researchers, and doctors work together to find out how MS affects the brain. This gives us clues about the type/s of drugs that might help. We grow brain cells in the lab, add the potential drugs, and measure the effect. Drugs that protect brain cells are then tested in the clinic to see how they help people with MS. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Centre of Research Excellence ($6,000,000); University of Tasmania ($177,384).
  • GRANT
    WHAT CAUSES MULTIPLE SCLEROSIS ONSET AND PROGRESSION?
    1 Jan 2024 - 31 Dec 2028
    People funded by this grant:
    • Young K,
    • Fletcher J,
    • Blackburn N
    Project Total: $3,653,279; In multiple sclerosis (MS) immune cells attack the brain. A person's genes, environment and lifestyle choices can influence whether they develop MS and the severity of disease. But we don't know how these factors alter brain cell function to start or worsen MS. To figure this out, we studied families with multiple members who have MS. We identified gene mutations carried by people with MS, with the potential to change brain cells function. We will now determine how brain cells are affected. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Ideas ($7,306,558); University of Tasmania ($480,068).
  • GRANT
    Unravelling the interplay between EBV genomics and host T cell immune regulation in multiple sclerosis
    1 Jun 2023 - 31 May 2027
    People funded by this grant:
    • Zhou Y,
    • Smith C,
    • Taylor B,
    • Khanna R,
    • Liu J
    Project Total: $1,999,237; Epstein Barr Virus (EBV) infects most people in childhood. In some people, it leads to Multiple Sclerosis (MS) but we dont know who or why. This project will evaluate the genetics of people with MS and the EBV in their cells to determine which genetic variants predispose to MS risk and how the immune response varies. We aim to understand the relationship between EBV and human genomes and how it leads to MS to guide future diagnostic, therapeutic, and preventive strategies. Funded by: Medical Research Future Fund - Grant - Multiple Sclerosis Research ($2,549,568); University of Tasmania ($105,480).
  • CONSULTANCY/CONTRACT RESEARCH
    Pregnancy and Multiple Sclerosis Outcomes
    1 Jan 2023 - 31 Dec 2024
    People funded by this grant:
    • Taylor B
    Project Total: $48,750; Retrospective, cross sectional, observational study to evaluate the impact of pregnancy on multiple sclerosis outcomes. Funded by: Monash University ($48,750); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Understanding MS MOOC extension
    1 Jan 2023 - 31 Dec 2028
    People funded by this grant:
    • Taylor B
    Project Total: $504,000; The Understanding MS is a massive open online course designed to educate and raise awareness about multiple sclerosis (MS), improving the lives of people with MS through increased knowledge, self-efficacy, and behaviour change. Funded by: MS Plus ($150,000); Multiple Sclerosis Australia ($354,000); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Merck Evolution - MS0200527-0080
    1 Jan 2020 - 31 Dec 2025
    People funded by this grant:
    • Taylor B,
    • Hussain A
    Project Total: $734,591; Commercially funded phase III, multicentre, randomised, parallel group, double blind, double dummy, active controlled study of evobrutinib compared with teriflunomide in participants with relapsing multiple sclerosis to evaluate the efficacy and safety (Double Blind 2 years followed by open label extension 3 years) Funded by: Merck & Co, Inc ($734,591); University of Tasmania.
  • GRANT
    The Menzies Multiple Sclerosis Flagship Program
    1 Jan 2020 - 30 Jun 2024
    People funded by this grant:
    • Taylor B,
    • Young K,
    • Charlesworth J,
    • van der Mei I,
    • Palmer A
    Project Total: $10,000,000; The Menzies Institute for Medical Research Multiple Sclerosis Flagship Program (MS Flagship) leverages the unique critical mass of MS research in Tasmania connected with Australian MS researchers, collaborators, MS societies and people with MS to address the gaps in the assessment, diagnosis and treatment of MS. Our work builds on our well-developed collaborations and laboratory, epidemiological, health economics and clinical research platforms. Our aim is to improve the clinical management of MS by slowing, halting and even reversing the rate of MS disease progression and to improve the quality of life and reduce the impact that MS has on individuals, their families and society. This project will expand the scope of the MS Flagship program and accelerate discoveries in MS research by supporting five key Activities: 1. Establish 'MS Stem' - a stem cell bank specifically designed to advance MS research 2. Gain a better understanding of the regeneration of brain cells and myelin repair 3. Expand our understanding of the rare genetic variation underpinning MS using genome sequencing of MS families and 'MS Stem' cell bank samples 4. Develop a treatment economic model which can identify cost-effective treatments and interventions for MS 5. Develop education tools and online resources, including an App specifically for people living with MS Funded by: Medical Research Future Fund - Grant - Accelerated Research ($10,000,000); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Understanding MS MOOC (Massive Open Online Course)
    1 Jan 2018 - 31 Dec 2022
    People funded by this grant:
    • Taylor B,
    • Claflin S,
    • van der Mei I
    Project Total: $506,000; Developing a massive open online course to improve the overall knowledge of MS in the wider MS community including those living with MS, their families and carers, as well as health care professionals, based on the hypothesis: 'Providing current, evidence-based information about MS will increase the knowledge and health literacy of course participants, resulting in improved outcomes for those living with MS and a greater understanding of MS in the general population?. Funded by: MS Plus ($306,000); The Select Foundation ($200,000); University of Tasmania ($215,796).